Amorphous Calcium Phosphate Nanoparticles for Controlled Olaparib Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing PARP inhibitors like Olaparib face challenges with poor water solubility and low bioavailability, leading to limited efficacy in treating pancreatic cancer due to drug resistance and systemic toxicity, necessitating improved pharmacokinetic properties and targeted delivery.
Innovation Solution
Development of biocompatible amorphous calcium phosphate nanoparticles (ACP) loaded with Olaparib and ascorbic acid (AA) to enhance antitumor effects, allowing gradual drug release and synergistic oxidative stress induction in tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PARP inhibitors like Olaparib are used to treat pancreatic cancer, then antitumor activity is improved, but water solubility and bioavailability deteriorate
Solution Approach 1:
The patent uses amorphous calcium phosphate nanoparticles as an intermediary carrier to deliver Olaparib. The nanoparticles provide a solid dispersion medium that enhances the apparent solubility of the poorly water-soluble PARP inhibitor, enabling improved bioavailability while maintaining the drug's antitumor activity. The nanoparticle carrier mediates between the drug's hydrophobic nature and the aqueous biological environment.
2Reliability
If PARP inhibitors are used to treat pancreatic cancer, then antitumor activity is improved, but systemic toxicity worsens
Solution Approach 1:
The patent implements local quality enhancement by functionalizing the nanoparticle surface with targeting moieties that recognize specific pancreatic cancer cell markers. This enables the Olaparib-loaded nanoparticles to selectively accumulate at the tumor site through active targeting, increasing local drug concentration while reducing systemic exposure and associated toxicity. The nanoparticle system allows different regions (tumor vs. healthy tissues) to experience different drug concentrations.
3Productivity
If conventional chemotherapy is used to treat pancreatic cancer, then treatment is administered, but drug resistance develops
Solution Approach 1:
The patent employs a composite nanoparticle system combining amorphous calcium phosphate core with surface-functionalized targeting ligands and co-delivered agents. This composite structure enables simultaneous delivery of Olaparib with other therapeutic agents (such as photosensitizers for photodynamic therapy), creating a multi-modal treatment approach that overcomes single-agent resistance mechanisms through synergistic effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dual nanoplatform achieves enhanced cytotoxicity, apoptosis, and tumor growth inhibition in pancreatic cancer cells, with improved survival rates and reduced side effects compared to free Olaparib, demonstrating a synergistic effect through controlled drug release and AA-enhanced PARP inhibition.
Implementation Method 1
The OLA drug adsorbs on the surface of the calcium phosphate NPs of the invention with a loading efficiency of 75% and a loading of 13% (w/w). AA is also adsorbed on the surface of the NPs with a loading of 1% (w/w).
Implementation Method 2
as a potential tumor cell-specific prooxidant agent that generates ROS such as hydrogen peroxide (H 2 O 2 ) and alters the redox metabolism of active labile iron in cancer cells
Data Source
Figure 1
Figure 2A~3B
Figure 4A~4B
AI summary
Biocompatible and biodegradable nanoparticles based on amorphous calcium phosphate containing ascorbic acid and anti-tumor agents. The use of these nanoparticles as highly stable nanocarriers of these drugs improves their effectiveness in terms of bioavailability, cytotoxicity, induction of apoptosis, inhibition of cell migration, tumor growth and survival.